What is TZIELD?

Also known as: teplizumab-mzwv

Tzield is a medicine prescribed to delay the onset of stage 3 type 1 diabetes – the stage when the body can’t make enough insulin on its own and requires insulin injections. Tzield is for adults and children 8 years of age and older who have stage 2 type 1 diabetes.

Candidates for Tzield must be at least 8 years of age and have tested positive for two or more type 1 diabetes-related autoantibodies, have abnormal blood sugar levels and do not have type 2 diabetes.

Tzield was developed by Provention Bio and Sanofi, and was approved by the Food and Drug Administration in 2022.

---

Reviewed by: Adriana Carrillo Iregui, MD

This page was last updated on: 1/29/2019 3:21:13 PM